White Papers

Launch Optimisation & Market Access

Launch optimisation in times of austerity

The pharmaceutical industry continues to innovate and stride ahead. However, in today’s challenging austere climate, those contemplating new product launches need to navigate many financial and competitive obstacles. Innovation is only as good as the commercialization strategy behind it. So what does austerity mean for the pharmaceutical industry and how can new product launches survive and achieve success?

Read More

Orphan Drug Development

A focus on orphan drug strategy

Rare diseases offer remarkable opportunities to the pharmaceutical industry, but the prospects are intertwined with clinical and regulatory challenges in addition to unique market dynamics. These challenges have a huge impact on both the development and commercialization processes. There are multiple Market Intelligence (MI) tools and initiatives that could prove valuable in supporting the drug development process. However the approaches used may need to be tweaked to cater to the rare disease environment.

Read More